Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The use of venetoclax in R/R AL amyloidosis

Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses the safety and efficacy of venetoclax in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis, referencing findings from a recently conducted retrospective analysis. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.